

RELEASE

July 25, 2013

Bad Homburg, Germany

Fresenius Kabi Receives 60601-1 3rd Edition Certification for Aurora Plasmapheresis System

Final step in CE marking process is completed

Fresenius Kabi announced today it has received 60601-1 3rd edition certification for the Aurora Plasmapheresis System designed for collection of plasma. 60601-1 3rd edition is the latest international consensus standard representing the current "state of the art" for medical device design and allows Fresenius Kabi to market the Aurora System in Europe. Aurora, which received U.S. FDA 510(k) Clearance in April 2012, represents the latest advancement in plasma collection technology from Fresenius Kabi.

"The Aurora System represents a significant advancement for plasma collection professionals," said William Cork, Executive Vice President and Chief Technology Officer of Fresenius Kabi's Medical Devices Division. "Aurora features powerful capabilities, such as an interactive touch-screen display with intuitive menus and icons, and works with Fenwal DXT Relay software." This software supports two-way, wireless data communication designed to eliminate manual steps and increase operator and donor satisfaction.

The Aurora System continues to use the company's proven and proprietary filtration separation method which enables the collection of virtually cell-free plasma and meets European requirements without further filtration.

The Aurora system offers new features that improve work flow and help assure a successful collection. Intuitive on-screen instructions simplify training for operators, and provide troubleshooting assistance. A LCD display allows donors themselves to see how their donation is progressing.

The Aurora system can support remote procedure set up and paperless documentation when used with the Fenwal DXT Relay software and a plasma center's donor management system. With remote procedure set up, the Aurora system can be

programmed automatically based on donor registration information. These features help assure data accuracy, documentation compliance, and a more streamlined procedure.

The Fenwal DXT Relay software also provides plasma center professionals with easy-to-read, on-demand reports that consolidate donor and procedure data from multiple Aurora systems at different locations. The reports track specific performance indicators and can be used to identify opportunities for operational improvement and training. The Fenwal DXT Relay software was built with open architecture so that it can seamlessly integrate with existing plasma center systems without requiring expensive, proprietary add-ons.

Plasma is the liquid portion of blood that contains valuable proteins used to treat burn victims, bleeding disorders, human immune deficiencies, and other chronic or genetic disorders. Unlike other blood components, which are stored at room temperature or refrigerated, plasma is frozen and thawed prior to fractionation or transfusion.

Plasmapheresis is an automated process in which plasma is taken from donated blood and the remaining components – primarily red cells and platelets – are returned to the donor. Source plasma is used by pharmaceutical companies that produce therapies from plasma-derived proteins.

###

Fresenius Kabi is a leading international health care company focusing on products for the therapy and care of critically and chronically ill patients inside and outside the hospital. The company develops, produces and markets pharmaceuticals and medical devices. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for whole blood collection and processing as well as for transfusion medicine and cell therapies. With the corporate philosophy of "caring for life", Fresenius Kabi is committed to supporting medical professionals in the best therapy of patients.

Fresenius Kabi has 30,668 employees worldwide (March 31, 2013).

In 2012, Fresenius Kabi's sales were €4,539 million and the company's EBIT was €934 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE & Co. KGaA.

Acquired by Fresenius Kabi in December 2012, Fenwal is focused on improving transfusion medicine through unique expertise in blood separation, collection, filtration, storage and transfusion. Fenwal offers a broad range of products and services for the automated and manual collection of blood and blood components.

For more information visit the company's website at www.fresenius-kabi.com.

To the extent this release contains forward-looking statements these are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Mats Henriksson (Chairman), Marc Crouton, John Ducker, Dr. Christian Hauer, Manfred M. Köhler, Thomas Mechtersheimer, Dr. Michael Schönhofen, Gerrit Steen
Chairman of the Supervisory Board: Dr. Ulf M. Schneider
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg - HRB 11654

###

Medical Devices Division

Fresenius Kabi AG

Else-Kröner-Straße 1

61352 Bad Homburg

Germany

T +49 6172 686 7265

F +49 6172 686 4728

Medical.Devices@fresenius-kabi.com

www.fresenius-kabi.com

Fenwal, Aurora and DXT are trademarks of Fenwal, Inc.